:: Healthcare BizDev ::

back to News

Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha (Evolocumab)

Source	Amgen, Inc.
Published Date	5/2/2017


Harvard Pilgrim Refines the Utilization Management Criteria to Help High-Risk Cardiovascular Patients Access Repatha Amgen (NASDAQ:AMGN) today announced from the World Medical Innovation Forum™ focused on cardiovascular disease that Harvard Pilgrim, a health services company providing healthcare coverage for nearly 2.7 million customers in the northeast region of the U.S.,1 has signed an outcomes-based refund contract with Amgen for Repatha® (evolocumab). This first-of-its-kind contract is based on the Repatha cardiovascular outcomes data that were recently presented at the American College of Cardiology 66th Annual Scientific Session. The contract provides Harvard Pilgrim with a rebate for the cost of Repatha for an eligible patient who has a heart attack or stroke while on Repatha. ...
View the entire Amgen, Inc. article
LinkedIn

Featured Companies

Thousand Oaks, CA

Wellesley Hills, MA

Company Representatives Featured

[Former Director, R&D Communications]
Amgen, Inc.

[Director Corporate Affairs]
Amgen, Inc.

[Former SVP of Global Coverage & Reimbursement]
Amgen, Inc.

[Former Chief Medical Officer]
Harvard Pilgrim Health Care


back to News